Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
Cerus Corporation (CERS)
Last cerus corporation earnings: 2/20 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cerus.com/investors/investor-overview/default.aspx
Company Research
Source: Seeking Alpha
Cerus Corporation inks FDA contract for Pathogen Reduction technologyCerus Corporation (CERSannouncedCerus is active in the field of blood products. It aims to develop and supply vital technologies and pathogen-protected blood components. Its main customer base consists of blood centers, hospitals and ultimately patients. Dr. Nina Mufti, program leader for both the Whole Blood and Red Blood Cell programs at Cerus said, “A whole blood PR solution would complement Cerus’ portfolio of marketed pathogen reduction products for platelets and plasma, as well as its INTERCEPT Red Blood Cell (RBCThe company’s lead product is INTERCEPT Blood System which delivers the full spectrum of blood transfusion products. It is the only company in blood transfusion segment to receive both the FDA approval and CE Mark for pathogen reduction of both plasma components and platelet. The system is currently available in the United States, Europe, the Commonwealth of Independent States, the Middle East and sele
Show less
Read more
Impact Snapshot
Event Time:
CERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERS alerts
High impacting Cerus Corporation news events
Weekly update
A roundup of the hottest topics
CERS
News
- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life [Yahoo! Finance]Yahoo! Finance
- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf LifeBusiness Wire
- Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients [Seeking Alpha]Seeking Alpha
- Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients [Yahoo! Finance]Yahoo! Finance
- Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery PatientsBusiness Wire
CERS
Earnings
- 3/5/24 - In-Line
CERS
Sec Filings
- 3/19/24 - Form 8-K
- 3/14/24 - Form 4
- 3/14/24 - Form 4
- CERS's page on the SEC website